---
document_datetime: 2025-12-21 12:16:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-hospira.html
document_name: levetiracetam-hospira.html
version: success
processing_time: 0.1422944
conversion_datetime: 2025-12-24 14:35:36.1601
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Levetiracetam Hospira

[RSS](/en/individual-human-medicine.xml/66931)

##### Authorised

This medicine is authorised for use in the European Union

levetiracetam Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Levetiracetam Hospira](#news-on)
- [More information on Levetiracetam Hospira](#more-information-on-levetiracetam-hospira-1484)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79304)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Levetiracetam Hospira is an epilepsy medicine. It can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation. This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one side of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear. Secondary generalisation occurs when the overactivity later reaches the whole brain.

Levetiracetam Hospira can also be used as an add-on to other anti-epileptic medicines to treat:

- partial-onset seizures with or without generalisation in patients from four years of age;
- myoclonic seizures (short, shock-like jerks of a muscle or a group of muscles) in patients from 12 years of age with juvenile myoclonic epilepsy;
- primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Levetiracetam Hospira is used as an alternative for patients when oral treatment is temporarily not feasible.

Levetiracetam Hospira contains the active substance levetiracetam and is a 'generic medicine'. This means that Levetiracetam Hospira contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Keppra.

Expand section

Collapse section

## How is Levetiracetam Hospira used?

Levetiracetam Hospira is given by infusion (drip into a vein) and it can only be obtained with a prescription.

The usual starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day. The daily dose can be increased up to 1,500 mg twice a day. For patients aged between 4 years and 17 years weighing less than 50 kg, the dose depends on body weight.

The use of Levetiracetam Hospira infusion should be temporary.

For more information about using Levetiracetam Hospira, see the package leaflet or contact your doctor or pharmacist.

## How does Levetiracetam Hospira work?

The active substance in Levetiracetam Hospira, levetiracetam, is an epilepsy medicine. Epilepsy is caused by excessive electrical activity in the brain. The exact way in which levetiracetam works is still unclear but it attaches to a protein called synaptic vesicle protein 2A, which is involved in the release of chemical messengers from nerve cells. This helps Levetiracetam Hospira to stabilise electrical activity in the brain and prevent seizures.

## How has Levetiracetam Hospira been studied?

The company provided data from the published literature on levetiracetam. Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Keppra, and do not need to be repeated for Levetiracetam Hospira.

As for every medicine, the company provided data on the quality of Levetiracetam Hospira. There was no need for 'bioequivalence' studies to investigate whether Levetiracetam Hospira is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Levetiracetam Hospira is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Levetiracetam Hospira?

Because Levetiracetam Hospira is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Levetiracetam Hospira approved?

The European Medicines Agency concluded that, in accordance with EU requirements, Levetiracetam Hospira has been shown to be comparable to Keppra. Therefore, the Agency's view was that, as for Keppra, the benefits of Levetiracetam Hospira outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Levetiracetam Hospira?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Levetiracetam Hospira have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Levetiracetam Hospira are continuously monitored. Suspected side effects reported with Levetiracetam Hospira are carefully evaluated and any necessary action taken to protect patients.

## Other information about Levetiracetam Hospira

Levetiracetam Hospira received a marketing authorisation valid throughout the EU on 8 January 2014.

Levetiracetam Hospira : EPAR - Medicine overview

English (EN) (155.33 KB - PDF)

**First published:** 20/01/2014

**Last updated:** 22/09/2021

[View](/en/documents/overview/levetiracetam-hospira-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-739)

български (BG) (165.61 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/bg/documents/overview/levetiracetam-hospira-epar-medicine-overview_bg.pdf)

español (ES) (148.16 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/es/documents/overview/levetiracetam-hospira-epar-medicine-overview_es.pdf)

čeština (CS) (161.26 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/cs/documents/overview/levetiracetam-hospira-epar-medicine-overview_cs.pdf)

dansk (DA) (146.69 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/da/documents/overview/levetiracetam-hospira-epar-medicine-overview_da.pdf)

Deutsch (DE) (143 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/de/documents/overview/levetiracetam-hospira-epar-medicine-overview_de.pdf)

eesti keel (ET) (135.34 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/et/documents/overview/levetiracetam-hospira-epar-medicine-overview_et.pdf)

ελληνικά (EL) (182.55 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/el/documents/overview/levetiracetam-hospira-epar-medicine-overview_el.pdf)

français (FR) (148.87 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/fr/documents/overview/levetiracetam-hospira-epar-medicine-overview_fr.pdf)

hrvatski (HR) (167.41 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/hr/documents/overview/levetiracetam-hospira-epar-medicine-overview_hr.pdf)

italiano (IT) (154.98 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/it/documents/overview/levetiracetam-hospira-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (192.14 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/lv/documents/overview/levetiracetam-hospira-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (168.1 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/lt/documents/overview/levetiracetam-hospira-epar-medicine-overview_lt.pdf)

magyar (HU) (177.3 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/hu/documents/overview/levetiracetam-hospira-epar-medicine-overview_hu.pdf)

Malti (MT) (170.76 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/mt/documents/overview/levetiracetam-hospira-epar-medicine-overview_mt.pdf)

Nederlands (NL) (148.87 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/nl/documents/overview/levetiracetam-hospira-epar-medicine-overview_nl.pdf)

polski (PL) (165.01 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/pl/documents/overview/levetiracetam-hospira-epar-medicine-overview_pl.pdf)

português (PT) (141.66 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/pt/documents/overview/levetiracetam-hospira-epar-medicine-overview_pt.pdf)

română (RO) (160.74 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/ro/documents/overview/levetiracetam-hospira-epar-medicine-overview_ro.pdf)

slovenčina (SK) (163.04 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/sk/documents/overview/levetiracetam-hospira-epar-medicine-overview_sk.pdf)

slovenščina (SL) (182.68 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/sl/documents/overview/levetiracetam-hospira-epar-medicine-overview_sl.pdf)

Suomi (FI) (152.99 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/fi/documents/overview/levetiracetam-hospira-epar-medicine-overview_fi.pdf)

svenska (SV) (131.04 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

22/09/2021

[View](/sv/documents/overview/levetiracetam-hospira-epar-medicine-overview_sv.pdf)

## Product information

Levetiracetam Hospira : EPAR - Product Information

English (EN) (260.68 KB - PDF)

**First published:** 20/01/2014

**Last updated:** 15/12/2025

[View](/en/documents/product-information/levetiracetam-hospira-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-778)

български (BG) (292.36 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/bg/documents/product-information/levetiracetam-hospira-epar-product-information_bg.pdf)

español (ES) (261.28 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/es/documents/product-information/levetiracetam-hospira-epar-product-information_es.pdf)

čeština (CS) (452.66 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/cs/documents/product-information/levetiracetam-hospira-epar-product-information_cs.pdf)

dansk (DA) (310.13 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/da/documents/product-information/levetiracetam-hospira-epar-product-information_da.pdf)

Deutsch (DE) (279.73 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/de/documents/product-information/levetiracetam-hospira-epar-product-information_de.pdf)

eesti keel (ET) (241.67 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/et/documents/product-information/levetiracetam-hospira-epar-product-information_et.pdf)

ελληνικά (EL) (303.44 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/el/documents/product-information/levetiracetam-hospira-epar-product-information_el.pdf)

français (FR) (258.1 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/fr/documents/product-information/levetiracetam-hospira-epar-product-information_fr.pdf)

hrvatski (HR) (273.93 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/hr/documents/product-information/levetiracetam-hospira-epar-product-information_hr.pdf)

íslenska (IS) (263.18 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/is/documents/product-information/levetiracetam-hospira-epar-product-information_is.pdf)

italiano (IT) (263.72 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/it/documents/product-information/levetiracetam-hospira-epar-product-information_it.pdf)

latviešu valoda (LV) (253 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/lv/documents/product-information/levetiracetam-hospira-epar-product-information_lv.pdf)

lietuvių kalba (LT) (243.99 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/lt/documents/product-information/levetiracetam-hospira-epar-product-information_lt.pdf)

magyar (HU) (315.36 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/hu/documents/product-information/levetiracetam-hospira-epar-product-information_hu.pdf)

Malti (MT) (296.6 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/mt/documents/product-information/levetiracetam-hospira-epar-product-information_mt.pdf)

Nederlands (NL) (264.4 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/nl/documents/product-information/levetiracetam-hospira-epar-product-information_nl.pdf)

norsk (NO) (260.3 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/no/documents/product-information/levetiracetam-hospira-epar-product-information_no.pdf)

polski (PL) (270.43 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/pl/documents/product-information/levetiracetam-hospira-epar-product-information_pl.pdf)

português (PT) (251.09 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/pt/documents/product-information/levetiracetam-hospira-epar-product-information_pt.pdf)

română (RO) (289.88 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/ro/documents/product-information/levetiracetam-hospira-epar-product-information_ro.pdf)

slovenčina (SK) (272.08 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/sk/documents/product-information/levetiracetam-hospira-epar-product-information_sk.pdf)

slovenščina (SL) (257.69 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/sl/documents/product-information/levetiracetam-hospira-epar-product-information_sl.pdf)

Suomi (FI) (422.63 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/fi/documents/product-information/levetiracetam-hospira-epar-product-information_fi.pdf)

svenska (SV) (243.03 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

15/12/2025

[View](/sv/documents/product-information/levetiracetam-hospira-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000315806 12/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Levetiracetam Hospira : EPAR - All Authorised presentations

English (EN) (13 KB - PDF)

**First published:** 20/01/2014

**Last updated:** 29/04/2014

[View](/en/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-82)

български (BG) (42.32 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/bg/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.12 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/es/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_es.pdf)

čeština (CS) (41.94 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/cs/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (11.91 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/da/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (11.99 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/de/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (11.89 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/et/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.46 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/el/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_el.pdf)

français (FR) (11.86 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/fr/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (40.73 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/hr/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.78 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/is/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_is.pdf)

italiano (IT) (11.92 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/it/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (37.59 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/lv/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (35.93 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/lt/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (21.53 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/hu/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.76 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/mt/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.08 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/nl/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (11.97 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/no/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_no.pdf)

polski (PL) (36.85 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/pl/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_pl.pdf)

português (PT) (14.85 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/pt/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.93 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/ro/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (34.65 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/sk/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (21.18 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/sl/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (11.75 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/fi/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (11.83 KB - PDF)

**First published:**

20/01/2014

**Last updated:**

29/04/2014

[View](/sv/documents/all-authorised-presentations/levetiracetam-hospira-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Levetiracetam Hospira Active substance levetiracetam International non-proprietary name (INN) or common name levetiracetam Therapeutic area (MeSH) Epilepsy Anatomical therapeutic chemical (ATC) code N03AX14

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.

Levetiracetam Hospira is indicated as adjunctive therapy

- in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible.

## Authorisation details

EMA product number EMEA/H/C/002783

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 23/10/2013 Marketing authorisation issued 07/01/2014 Revision 28

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Levetiracetam Hospira : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (152.74 KB - PDF)

**First published:** 12/05/2025

**Last updated:** 15/12/2025

[View](/en/documents/procedural-steps-after/levetiracetam-hospira-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Levetiracetam Hospira : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (203.25 KB - PDF)

**First published:** 29/04/2014

**Last updated:** 12/05/2025

[View](/en/documents/procedural-steps-after/levetiracetam-hospira-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Levetiracetam Hospira : EPAR - Public assessment report

Adopted

Reference Number: EMA/777160/2013

English (EN) (234.23 KB - PDF)

**First published:** 20/01/2014

**Last updated:** 20/01/2014

[View](/en/documents/assessment-report/levetiracetam-hospira-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Levetiracetam Hospira

Adopted

Reference Number: EMA/443446/2013

English (EN) (78.71 KB - PDF)

**First published:** 25/10/2013

**Last updated:** 25/10/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-levetiracetam-hospira_en.pdf)

#### News on Levetiracetam Hospira

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 October 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-october-2013) 25/10/2013

#### More information on Levetiracetam Hospira

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-885)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Levetiracetam Hospira : EPAR - Product information - tracked changes

English (EN) (115.77 KB - DOCX)

**First published:** 17/09/2025

[View](/en/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-222)

български (BG) (161.99 KB - DOCX)

**First published:**

17/09/2025

[View](/bg/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_bg.docx)

español (ES) (125.73 KB - DOCX)

**First published:**

17/09/2025

[View](/es/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_es.docx)

čeština (CS) (117.92 KB - DOCX)

**First published:**

17/09/2025

[View](/cs/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (145.94 KB - DOCX)

**First published:**

17/09/2025

[View](/da/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (120.55 KB - DOCX)

**First published:**

17/09/2025

[View](/de/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (99.11 KB - DOCX)

**First published:**

17/09/2025

[View](/et/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (149.05 KB - DOCX)

**First published:**

17/09/2025

[View](/el/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_el.docx)

français (FR) (111.04 KB - DOCX)

**First published:**

17/09/2025

[View](/fr/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (134.75 KB - DOCX)

**First published:**

17/09/2025

[View](/hr/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (115.81 KB - DOCX)

**First published:**

17/09/2025

[View](/is/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_is.docx)

italiano (IT) (114.58 KB - DOCX)

**First published:**

17/09/2025

[View](/it/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (109.24 KB - DOCX)

**First published:**

17/09/2025

[View](/lv/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (115.15 KB - DOCX)

**First published:**

17/09/2025

[View](/lt/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (158.19 KB - DOCX)

**First published:**

17/09/2025

[View](/hu/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (119.17 KB - DOCX)

**First published:**

17/09/2025

[View](/mt/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (128.81 KB - DOCX)

**First published:**

17/09/2025

[View](/nl/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (112.47 KB - DOCX)

**First published:**

17/09/2025

[View](/no/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_no.docx)

polski (PL) (123.34 KB - DOCX)

**First published:**

17/09/2025

[View](/pl/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_pl.docx)

português (PT) (108.11 KB - DOCX)

**First published:**

17/09/2025

[View](/pt/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_pt.docx)

română (RO) (140.97 KB - DOCX)

**First published:**

17/09/2025

[View](/ro/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (129.65 KB - DOCX)

**First published:**

17/09/2025

[View](/sk/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (107.07 KB - DOCX)

**First published:**

17/09/2025

[View](/sl/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (115.29 KB - DOCX)

**First published:**

17/09/2025

[View](/fi/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (111.48 KB - DOCX)

**First published:**

17/09/2025

[View](/sv/documents/product-information-tracked-changes/levetiracetam-hospira-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 15/12/2025

## Share this page

[Back to top](#main-content)